Summary This retrospective study evaluates the types and incidences of sexual disturbances and fertility distress in patients cured from testicular cancer and examines whether there is an effect resulting from different treatment modalities. A self-reported questionnaire was sent to 124 randomly selected patients who were treated at Hanover University Medical School between 1970 and 1993. Ninety-eight patients were included in the study, representing a response rate of 78%. All patients had been in complete remission (CR) for at least 24 months. The median age at diagnosis was 28 years (range 17-44). The median follow-up at the time of study was 12.0 years (range 2.8-25.6). Twenty patients (20%) had been treated for seminomatous and 78 patients (80%) for non-seminomatous germ cell tumours. Treatment included surveillance (7%), primary retroperitoneal lymph node dissection (RPLND) (13%), chemotherapy (CT) (33%), CT + secondary resection of residual retroperitoneal tumour mass (SRRTM) (43%) and infradiaphragmatic radiotherapy (4%). Patients receiving two treatment modalities (CT+SRRTM) reported more frequent an unfulfilled wish for children. Inability of ejaculation was clearly associated with RPLND and SRRTM. Subjective aspects of sexuality, like loss of sexual drive and reduced erectile potential, occurred only in a minority of patients after treatment. No abnormalities were observed concerning the course of pregnancies of partners. In conclusion, sexual dysfunction and infertility are common long-lasting sequelae in testicular cancer survivors affecting approximately 20% of patients. The relative risk for infertility appeared to be elevated for patients treated with the combination of CT+SRRTM. Twenty-one of 40 patients were able to fulfil their wish for children, and no congenital abnormalities were observed in these children.
Testicular cancer is a curable cancer which mostly affects men between 20 and 35 years of age. Major progress was achieved with the introduction of cisplatin into combination chemotherapy regimens, yielding cure rates of 70-85% in patients with metastatic disease (Einhorn, 1990; Bokemeyer, 1998) . Since most patients with testicular cancer are of a young age, the impact of therapy on sexual function and fertility has become increasingly important. Testicular cancer patients may have a reduced spermatogenesis ('hypospermia') at diagnosis (Hendry et al, 1983; Berthelsen and Skakkebaek, 1984; Cassileth and Steinfeld, 1987; Moynihan, 1987; Nijman et al, 1987; Fossa et al, 1988; Sleijfer et al, 1995) and after orchidectomy (Lampe et al, 1997) , and only between 22 and 63% of patients fulfil the definition of normospermia at diagnosis (Hendry et al, 1983; Fossa et al, 1985; Nijman et al, 1987; Lampe et al, 1997) . Three disease-associated conditions, local structural abnormalities detected by biopsy of the contralateral testis, the presence of sperm antibodies and endocrine factors, may be responsible (Berthelsen and Skakkebaek, 1984; Guazzieri et al, 1985) . Treatment-related factors have additionally been identified, for example decrease of testosterone levels after orchidectomy. However, no strong correlation was demonstrable between testosterone serum concentration and erection (Buena et al, 1993; van Basten et al, 1995) . Leydig cell function as well as testosterone production can be affected by radio-and chemotherapy (von Eschenbach, 1980; Aass et al, 1991) . Irradiation may cause small vessels disease and peripheral neuropathy resulting in erectile dysfunction (Fossa et al, 1980; von Eschenbach, 1980; Tomic et al, 1983; Goldstein et al, 1984; Fossa et al, 1986) . The possible organic-biologic effects of chemotherapy itself are also complex, including temporary reduction of testosterone levels, hyperprolactinaemia, induction of vascular damage and peripheral neuropathy (El-Beheiry et al, 1988; Aass et al, 1991; van Basten et al, 1997a) . Retroperitoneal lymph node dissection (RPLND) may cause permanent dry ejaculation due to the surgical interruption of retroperitoneal sympathetic nerves (Drasga et al, 1983) . The different effects of treatment on sexual functioning make their evaluation a complex problem, particularly in patients treated with more than one therapeutic modality. Large differences regarding the frequencies of sexual dysfunctions and the influence of different treatments are reported in the literature (Rieker et al, 1985 (Rieker et al, , 1989 Schover and Eschenbach, 1985; Schover et al, 1986; Gritz et al, 1989; Tinkler et al, 1992; Aass et al, 1993; Bloom et al, 1993; Arai et al, 1997; Jonker-Pool et al, 1997) . The aim of the present descriptive investigation was to evaluate the incidence of long-term effects on sexuality and try to identify treatment-related differences.
Long-term effects on sexual function and fertility after treatment of testicular cancer
PATIENTS AND METHODS
The medical records of testicular cancer patients treated at the Department of Hematology/Oncology of Hanover University Medical School between 1970 and 1993 were reviewed. A written self-report questionnaire concerning sexual function was sent to 124 patients who were randomly selected and who had had no evidence of disease for more than 2 years. Since no adequate validated questionnaire was available at the begining of study it was designed in corporation with the Department of Medical Psychology and the Department of Gynaecology at Hanover University Medical School. The questionnaire consisted of 41 issues related to fertility and sexual function before and after treatment, e.g. decrease in sexual response (libido, sexual drive, erection, orgasm), ejaculation function, changes in sexual activity and satisfaction, as well as items concerning child-bearing, course of pregnancy and state of health of offspring, and demographics. For the variable 'intensity of sexual life' (including the 'intensity of orgasm' (0 = no orgasm, 1 = pronounced decrease, 2 = slighty decreased, 3 = normal feeling) and the 'frequency of sexual intercourse' (0 = never, 1 = rarely, 2 = frequently, 3 = very often)) answers were ranked on a four-point scale (score). Medical information was obtained from the patients' records. Clinical staging of patients was available according to the Lugano Classification (Cavalli et al, 1980) . Patients were divided into four subgroups, according to the following treatment modalities: (1) orchidectomy and surveillance, SV; (2) primary retroperitoneal lymph node dissection, RPLND; (3) cisplatin-based combination chemotherapy, CT; (4) combination of chemotherapy and secondary surgery, CT+SRRTM. Four patients who had received infradiaphragmatic radiotherapy (RT) were not considered in the analysis comparing different treatment modalities due to the small number of patients available. The applied chemotherapy regimens are summarized in Table 1 (Williams et al, 1987; Loehrer et al, 1988; Einhorn, 1990; Harstrick et al, 1991; Schmoll et al, 1993; Bokemeyer et al, 1996) . The differences in sexual dysfunctions between the treatment subgroups were tested with the χ 2 -test or Fisher's exact test for categorial variables, and Kruskal-Wallis test and the Wilcoxon test for continuous variables. Differences were considered to be statistically significant at P-values less than 0.05.
RESULTS

Patients' characteristics
Of 124 evaluable patients from our registry, 26 patients (21%) did not return the questionnaire. Thus, aspects of sexuality and fertility were assessed in 98 men at a median follow-up period of 12.0 years after the diagnosis of testicular cancer (range 2.8-25.6). Twenty patients (20%) had been treated for seminomatous and 78 (80%) for non-seminomatous germ cell tumours. Treatment included RPLND alone in 13 patients (13%), radiotherapy (RT) alone in four patients (4%), CT alone in 32 patients (33%), and 42 patients underwent CT+SRRTM (43%). Seven patients underwent orchidectomy alone and surveillance for stage I disease (7%). Patients' characteristics are outlined in detail in Table 2 .
Pretreatment fertility status and fatherhood after treatment
Thirty-nine (40%) patients had fathered 53 children before the diagnosis of testicular cancer (Table 2 ). All 53 children with a median age of 14.5 years (range 12.2-17.3) at the time of this investigation were reported to have developed normally. No pregnancies occurred during any cancer treatment.
Twenty-one of 40 (53%) patients who reported a wish for children had fathered children at a median time of 54 months after the end of treatment (3-108 months). Additionally, two women interrupted gravidity at 8 months and at 2 years after the end of cancer treatment of their male partner. Nineteen of 40 (48%) patients who tried to obtain conception, have been unsuccessful after a median duration of nearly 5 years. Pathological semen analysis ('azoospermia'/< 1 × 10 6 ml -1 ) could be identified in 15 patients (79%) and permanent dry ejaculation in one patient (5%). Two patients were found to suffer from psychosocial distress causing reduced erectile potential (11%). In one case the spouse did not want to attain pregnancy (5%). In relation to the treatment modalities, patients treated with CT+SRRTM reported an unfulfilled wish for children more often (31%) as compared to patients belonging to the CT (13%, P = 0.03), SV (14%), or RPLND (7%) groups. Twenty of 87 patients (20%) scheduled to receive CT or RPLND were offered sperm cryopreservation before treatment. Only eight of those patients (40%) had accepted sperm-banking, two of whom were planning in-vitro fertilization (25%). None of the infertile patients planned to adopt children in the near future (Table 3) .
Courses of pregnancies in women with testicular cancer patients as partners
Except for one child with a low birth weight (2225 g) (CT), all other 20 women had a normal course of pregnancy. Minor complications (bleeding and premature start of labour) were observed in two women. Nine of 21 pregnant women (43%) chose a higher rate of pregnancy check-up which was measured by the number of amniocenteses (four of 21), ultrasound examinations or physician consultations. Nineteen women had a spontaneous delivery, and in two women a Caesarian section was carried out. The mean birth weight and height were 3398.5 g (range 2225-4070) and 51.5 cm (range 46-56). Three spontanous abortions were reported in the total cohort. All abortions occurred before the 14th week of gravidity. Concerning the health status of the offspring, there were no major birth defects or complications during and after birth. All children have been reported to develop normally up to a median age of 62 months (range 1-180). Two children with congenital defects, one with cryptorchidism and one with hip dysplasia, were identified (Table 4) .
Sexual dysfunctioning
The incidences of various types of sexual dysfunctions are listed in Table 5 . In total, 29 patients (30%) were found to have ejaculation problems after treatment. A significantly higher incidence was observed in patients who underwent RPLND alone (45%, P = 0.03) or a secondary resection after chemotherapy (CT+SRRTM = 55%, P = 0.01) as compared to patients treated with chemotherapy alone (11%). In three of 29 patients (10%) the ejaculatory function recovered between 1 and 3 years after treatment. Sixteen patients reported a decrease in the quantity of semen fluid production: six patients reported slight and ten patients severe reductions. The reduction of semen fluid quantity appears to be related to RPLND (31%, P = 0.06). Eight per cent of patients reported dissatisfaction with their sexual life before the diagnosis of cancer. Two patients reported loss of sexual drive (2%) and one patient reported a reduced erectile potential (1%). A score to self-adjust the intensity of sexual life (including the frequency of sexual intercourse and the intensity of orgasms) showed no difference before and after treatment for all patients, with a mean score of 2.3 (P = 0.51). As expected, the score significantly decreased during treatment (data not shown), but recovered almost completely after treatment, with no differences between treatment groups. 'Loss of sexual drive', 'reduced erectile potential' and 'dissatisfaction with sexual life' were observed more frequently after treatment compared to pretreatment status but this was not statistically significant. The highest incidences regarding those disorders was seen in patients receiving CT+SRRTM (not significant). Age and duration of follow-up did not influence the incidence of sexual disorders.
DISCUSSION
Despite a reasonable number of retrospective studies investigating the influence of treatment on sexual function, the question remains open whether and in what degree testicular cancer patients are at risk for sexual morbidity (Rieker et al, 1985 (Rieker et al, , 1989 Schover and Eschenbach, 1985; Schover et al, 1986; Moynihan, 1987; Gritz et al, 1989; Stoter et al, 1989; Tinkler et al, 1992; Aass et al, 1993; Arai et al, 1997; Jonker-Pool et al, 1997) . The available data vary widely and a correlation to different treatment modalities is lacking in most studies. Furthermore, the comparison of different studies is difficult due to differences in irradiation procedures, 
chemotherapy regimens, composition of the cohort of patients and in the aims of each study. We report nearly 100 patients who underwent different treatment modalities for testicular germ cell tumour between 1970 and 1993. This descriptive study provides data about sexual function, fertility status/distress and the adaptive behavioural responses, and reports on the courses and outcome of pregnancies after treatment. For testicular cancer survivors the highest child-bearing potential after treatment has been reported in seminoma patients who were treated with radiation therapy alone. The lowest rates were observed in patients who had undergone retroperitoneal surgery plus cisplatin-based chemotherapy (Rieker et al, 1985 (Rieker et al, , 1989 Schover and Eschenbach, 1985; Petersen et al, 1994; Arai et al, 1997) . In this series patients receiving CT+SRRTM reported childlessness more frequently compared to patients treated with CT alone. Despite the observation of a comparable decrease in subjective sexual aspects (libido, orgasm, satisfaction) in both treatment groups, the combined treatment resulted in a higher fertility distress. This is in accordance with a report by Arai et al (1997) who reported a 21% difference between both groups concerning desire for children (68% vs 47%). Compared to the frequency of unintentional childlessness in the German population (about 17%), only patients receiving both chemotherapy and retroperitoneal surgery appear to have a higher incidence of an unfulfilled wish for children, whereas for all other treatment groups the incidence was lower (Bruckert, 1991) .
Today, sperm-banking may be beneficial even for patients who are subfertile at the time of diagnosis, because the techniques of sperm preservation and in-vitro fertilization rapidly advances. Sperm-banking awareness is one of several possible fertility adjustment responses, besides adoption awareness, fertility testing and trying to father children and fertility distress (Rieker et al, 1990) . The psychological aspects of infertility, its psychosomatic components on health and sexuality have been described elsewhere (Burns, 1987) . In the current investigation, 20 of 87 (23%) patients who underwent CT or RPLND reported that cryopreservation had been offered to them. Forty per cent of them had performed sperm-banking and two of those patients were planning in vitro fertilization. Although sperm-banking awareness was somewhat lower than described by Rieker et al (1990) , the number of men who had performed sperm-banking was in the same range. In our investigation, none of the patients were planning to adopt children in the near future. In the above mentioned study, 21% of men considered adoption and 3% had adopted a child.
Although our cohort of patients with 21 born children is too small for definitive conclusions, we did not observe an elevated rate of complications during pregnancies in the partners of our testicular cancer patients. The rate of pregnancy check-up appeared to be higher as compared to the general population. Four of 21 women underwent amniocentesis (19%) and approximately 40% consulted their physician earlier than is the norm. Altogether, three of 26 pregnancies were miscarriages. No adverse pregnancy outcome defined as fetal or neonatal death or severe congenital malformation was observed, with the exception of the premature birth of a live-born infant weighing 2225 g. There are only limited data about the pregnancy outcome of partners of male cancer survivors (Brenner et al, 1985; Stoter et al, 1989; Senturia and Peckham, 1990; Byrne and Mulvihill, 1991) . Another investigation regarding children fathered after the remaining gonad had been exposed to chemotherapy had also found no evidence of an increased risk of congenital malformations compared to matched controls (Dodds et al, 1993) . A recent investigation showed no significantly increased risk of non-hereditary cancer among the offspring of survivors of cancer in childhood (Sankila et al, 1998) . No pregnancies occurred during the actual cancer treatment period; patients were advised to perform birth control during therapy.
It has been demonstrated that testicular cancer can affect sexual function (Jonker-Pool et al, 1997) . The incidences of subjective aspects, like 'loss of libido', 'erectile dysfunction' and 'reduced satisfaction with sexual life' were 7%, 9% and 13% respectively. Data available from the literature ranged from 4% up to 38% in different reports (Rieker et al, 1985; Schover and Eschenbach, 1985; Moynihan, 1987; Schover, 1987; Fossa et al, 1988; Gritz et al, 1989; Jonker-Pool et al, 1997) . It has been suggested that sexual dysfunctions are related to the intensity and the modality of the treatment. A low incidence of sexual dysfunction was observed in surveillance patients or in seminoma patients undergoing irradiation (Rieker et al, 1985; Schover and Eschenbach, 1985; Jonker-Pool et al, 1997) . Patients who underwent chemotherapy (± SRRTM) appeared to be at the highest risk for sexual dysfunction (Rieker et al, 1985; Arai et al, 1997; Jonker-Pool et al, 1997) . With the exception of absence of ejaculation, no major difference has been reported between the CT and CT+SRRTM therapies (Arai et al, 1997; Jonker-Pool et al, 1997; van Basten et al, 1997b ; own series). According to expectations, absence of antegrade ejaculation was reported by 45% and 55% (P = 0.03 and P = 0.01) of our patients undergoing RPLND or CT+SRRTM. Possible damage is related to the extent of the retroperitoneal surgical approach (Nijman et al, 1987; Jones et al, 1993) . All of our patients with primary RPLND had stage II disease and underwent unilateral RPLND either as a radical procedure (before 1992) or as a modified RPLND (after 1992). Secondary resection of residual masses after chemotherapy was usually performed as a lumpectomy (Hartmann et al, 1997a (Hartmann et al, , 1997b .
Absence of ejaculation was reported by three patients treated with CT alone (9%). Chemotherapy may affect the hormonal, vascular and nervous systems (van Basten et al, 1995 (van Basten et al, , 1997a . All of these systems are important for sexual function and their disturbance may thus cause ejaculatory problems. This rare observation was reported previously by another investigator in 7% of chemotherapy-treated patients (Arai et al, 1997) . A decreased erectile potential was observed in 9% of our patients, which is within the range of other investigations (Arai et al, 1997; Jonker-Pool et al, 1997) . A higher incidence has been reported in patients undergoing radiation therapy (15-48%) (Arai et al, 1997; Jonker-Pool et al, 1997; van Basten et al, 1997a) .
In conclusion, long-lasting sexual problems after therapy for testicular cancer are present in approximately one-fifth of patients undergoing treatment for testicular germ cell tumour. On the other hand, the majority of patients have not reported infertility or sexual dysfunction-related symptoms. Ejaculation disturbances were found in a large number of patients undergoing RPLND. The relative risk for infertility appears to be elevated for patients treated with the combination of CT+SRRTM leading to a definitve number of infertile men. The courses of pregnancies in partners of testicular cancer survivors did not differ from those of the general population and no major birth defects or serious chronic diseases were detectable in any of 21 children. This finding confirms other studies in long-term survivors of cancer treatment which revealed no increased risk for congenital abnormalities or late effects in the offspring.
